Skip to content
DataLookout
Start free
Menu

NCT07796997

GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of postoperative pancreatic fistula (POPF)
Timeframe: Until 30 days after surgery

Secondary (3)

Postoperative morbidity and perioperative complications
Time to initiation of adjuvant chemotherapy following pancreatectomy
Overall survival To evaluate overall survival (OS) following pancreatectomy between the hydrocortisone and standard-of-care (SOC) arms

Arms and interventions

Perioperative hydrocortisone and pancreatic resectionExperimental

Participants will receive hydrocortisone 100 mg intravenously (IV) at the time of pancreatic resection, followed by two additional 100 mg IV doses administered every 8 hours (three doses total).

Standard perioperative care and pancreatic resectionActive comparator

Participants will receive no perioperative steroids beyond routine clinical management in addition to pancreatic resection.

Drugs: Hydrocortisone

Procedures: Pancreatic resection

Sites

1 site in 1 country

  • University of Illinois Cancer CenterChicago, Illinois, United States